DPHL v2: An updated and comprehensive DIA pan-human assay library for quantifying more than 14,000 proteins.

Xue, Z.; Zhu, T.; Zhang, F.; Zhang, C.; Xiang, N.; Qian, L.; Yi, X.; Sun, Y.; Liu, W.; Cai, X.; Wang, L.; Dai, X.; Yue, L.; Li, L.; Pham, T. V.; Piersma, S. R.; Xiao, Q.; Luo, M.; Lu, C.; Zhu, J.; Zhao, Y.; Wang, G.; Xiao, J.; Liu, T.; Liu, Z.; He, Y.; Wu, Q.; Gong, T.; Zheng, Z.; Ye, J.; Li, Y.; Jimenez, C. R.; A, J.; Guo, T.

doi:10.1101/2023.01.07.523067

bioRxiv · 10.1101/2023.01.07.523067

DPHL v2: An updated and comprehensive DIA pan-human assay library for quantifying more than 14,000 proteins.

Xue, Z.·Zhu, T.·Zhang, F.·Zhang, C.·Xiang, N.·Qian, L.·Yi, X.·Sun, Y.·Liu, W.·Cai, X.·Wang, L.·Dai, X.·Yue, L.·Li, L.·Pham, T. V.·Piersma, S. R.·Xiao, Q.·Luo, M.·Lu, C.·Zhu, J.·Zhao, Y.·Wang, G.·Xiao, J.·Liu, T.·Liu, Z.·He, Y.·Wu, Q.·Gong, T.·Zheng, Z.·Ye, J.·Li, Y.·Jimenez, C. R.·A, J.·Guo, T.

View original source ↗Export metadata ↓

Abstract

A comprehensive pan-human spectral library is critical for biomarker discovery using mass spectrometry (MS)-based proteomics. DPHL v1, a previous pan-human library built from 1096 data-dependent acquisition (DDA) MS data of 16 human tissue types, allows quantifying 10,943 proteins. However, a major limitation of DPHL v1 is the lack of semi-tryptic peptides and protein isoforms, which are abundant in clinical specimens. Here, we generated DPHL v2 from 1608 DDA-MS data acquired using Orbitrap mass spectrometers. The data included 586 DDA-MS newly acquired from 17 tissue types, while 1022 files were derived from DPHL v1. DPHL v2 thus comprises data from 24 sample types, including several cancer types (lung, breast, kidney, and prostate cancer, among others). We generated four variants of DPHL v2 to include semi-tryptic peptides and protein isoforms. DPHL v2 was then applied to a publicly available colorectal cancer dataset with 286 DIA-MS files. The numbers of identified and significantly dysregulated proteins increased by at least 21.7% and 14.2%, respectively, compared with DPHL v1. Our findings show that the increased human proteome coverage of DPHL v2 provides larger pools of potential protein biomarkers.

Explore related subjects

bioinformatics Preprint

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Xue, Z., Zhu, T., Zhang, F., Zhang, C., Xiang, N., Qian, L., Yi, X., Sun, Y., Liu, W., Cai, X., Wang, L., Dai, X., Yue, L., Li, L., Pham, T. V., Piersma, S. R., Xiao, Q., Luo, M., Lu, C., Zhu, J., Zhao, Y., Wang, G., Xiao, J., Liu, T., Liu, Z., He, Y., Wu, Q., Gong, T., Zheng, Z., Ye, J., Li, Y., Jimenez, C. R., A, J., Guo, T.. 2023-01-08. DPHL v2: An updated and comprehensive DIA pan-human assay library for quantifying more than 14,000 proteins.. https://doi.org/10.1101/2023.01.07.523067

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Accelerating discovery and integration from RNA to Protein with R2T2P

Integrating transcriptomics and proteomics data remains an unmet challenge in the post-genomics era, discouraging researchers from pursuing integrative approaches to molecular biology research. Leveraging the power of translation profiling, we present RNA to Translation to Protein (R2T2P), a computational platform integrating genome-guided transcriptome assembly with identification of translation and proteins, including a tailored differential analysis framework and support for multiple reference transcriptomes. We applied R2T2P to investigate a cellular model of facioscapulohumeral muscular dystrophy (FSHD), where ectopic expression of the DUX4 retrogene in skeletal muscle triggers significant alterations in transcription and RNA metabolism. We uncovered hundreds of uncharacterized, highly overexpressed RNAs, including antisense and alternative transcripts, and quantified their contribution to translatome and proteome. Re-analysis of expression datasets from patient-derived myotubes and muscle biopsies validated this alternative transcriptome in FSHD patients, adding a reservoir of bona-fide novel molecular actors in a rare disease. Available at https://github.com/nfdata-omics/R2T2P/, R2T2P is a flexible and powerful workflow in modern integrative biology.

bioinformatics↗

bioRxiv2026

MorphoANOVA: Dissecting Histology-Gene Expression Relationships in Spatial Transcriptomics

Spatial transcriptomics (ST) measures the expression of hundreds to thousands of genes within tissue architecture, often accompanied by histology images. However, it remains challenging to systematically characterize which genes exhibit associations with tissue morphology, whether these associations vary spatially, and which genes show additional spatial expression patterns beyond those captured by morphology. Here we introduce MorphoANOVA, a gene-wise statistical framework for characterizing morphology--expression relationships across genes measured by ST. Using nested spatially varying coefficient models and sequential ANOVA, MorphoANOVA assesses slide-wide associations with an H\&E-derived morphology feature, location-specific changes in these associations, and additional spatial variation after accounting for the selected feature. The resulting statistics enable gene prioritization and pathway enrichment analysis, while spatial component maps support the interpretation of individual genes. Simulations demonstrate MorphoANOVA's ability to distinguish the modeled components and recover their spatial patterns. Applications to human cortex and breast cancer identify biological programs associated with different morphology--expression patterns and reveal distinct relationships with cell composition. Across three HER2-positive breast cancer patients, invasive-cancer marker genes consistently exhibit stronger evidence of location-specific morphology associations. MorphoANOVA thus provides a framework for systematically interpreting spatial gene-expression patterns in relation to tissue morphology.

bioinformatics↗

bioRxiv2026

Evaluation effects can rival reported concordance gains in cross-cancer survival prediction

Studies of cross-cancer learning for survival prediction from tumour omics have reported concordance gains of 0.020 and 0.045, but how such gains compare with evaluation effects remains unclear. We examined these effects across 13 TCGA cancers (5,761 patients, 1,526 disease-specific deaths), using five repeats of five-fold cross-validation and paired bootstrap intervals. When model selection did not use test data, our borrowing model gained 0.009 (95% interval 0.001 to 0.016) over its target-fitted reference when cancers received equal weight (post hoc). Random-effects pooling gave a gain of 0.002 (-0.002 to 0.006), with most weight assigned to cancers where the model made little use of the pretrained score. Choosing the fusion weight on test splits raised the apparent equal-weight gain to 0.017. We reimplemented a published method, VAECox, which showed no pretraining gain over random initialisation at the last or validation-selected training step. Choosing each network's best test step, as the published code does, raised concordance by 0.03 to 0.05 across the 13-cancer and ten-cancer overall-survival settings, but barely changed the difference between networks. In a constructed post hoc experiment, choosing the best test step only for the pretrained network changed the equal-weight mean difference from -0.004 to +0.045 (+0.035 to +0.054). Across seven multi-omics comparisons, estimates from single five-fold runs differed from their cancer's five-run mean by at least 0.02 in 11% to 42% of runs. Concordance was about 0.02 lower at held-out tissue source sites. Interpreting a reported gain therefore requires each model's selection rule, variation across repeated partitions, the weighting of cancers and the evaluation population.

bioinformatics↗